- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT06855043
Lille lungerundersøgelse
Pilotundersøgelse af sen overfladeaktivt terapi med budesonid til forebyggelse af bronchopulmonal dysplasi hos ekstremt for tidligt spædbørn
This clinical trial is being done to evaluate the safety and clinical response of late surfactant treatment with budesonide in extremely preterm infants requiring mechanical ventilation at 7-14 days of age.
Studieoversigt
Status
Intervention / Behandling
Detaljeret beskrivelse
Primary Objective
• To evaluate safety of late surfactant therapy with budesonide in extremely preterm infants.
Secondary Objectives
- To evaluate the oxygenation response to late surfactant therapy with budesonide in extremely preterm infants at 48 hours and 7 days after completion of the study intervention
- To evaluate respiratory outcomes following administration of late surfactant therapy with budesonide
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Fase 2
- Fase 1
Kontakter og lokationer
Studiekontakt
- Navn: Meg Baker
- E-mail: meg.baker@wisc.edu
Undersøgelse Kontakt Backup
- Navn: Dinushan Kaluarachchi, MBBS
- Telefonnummer: (608) 417-6849
- E-mail: kaluarachchi@pediatrics.wisc.edu
Studiesteder
-
-
Wisconsin
-
Madison, Wisconsin, Forenede Stater, 53792
- American Family Children's Hospital
-
Kontakt:
- Dinushan Kaluarachchi, MBBS
- Telefonnummer: 608-417-6849
- E-mail: kaluarachchi@pediatrics.wisc.edu
-
Madison, Wisconsin, Forenede Stater, 53715
- Meriter Hospital
-
Kontakt:
- Dinushan Kaluarachchi
- Telefonnummer: 608-417-6849
- E-mail: kaluarachchi@pediatrics.wisc.edu
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Neonate Inclusion Criteria:
- Gestational age 22 0/7 to 28 6/7 weeks at birth
- Age 7-14 days
- Need invasive mechanical ventilatory support and a Fraction of Inspired Oxygen (FiO2) greater than or equal to 0.3
Birthing Parent Inclusion Criteria:
- Have a baby who meets neonate eligibility criteria and enrolls in the study.
Neonate Exclusion Criteria:
- Major congenital anomalies including congenital lung malformations and congenital diaphragmatic hernia and/or genetic disorders
- Alternative, acute clinical etiology of respiratory deterioration or increased ventilatory requirements (e.g., sepsis, pneumonia, etc.)
- History of pulmonary hemorrhage
- Antibiotic use within 48 hours
- Indomethacin or Ibuprofen use within 72 hours
- Prior treatment with corticosteroids for prevention of lung disease
- Not expected to survive for greater than 7 days at enrollment
- Determined to be unstable by the clinical team
- Enrolled in a conflicting clinical trial
- Have a birth parent aged less than 18 years
- Parent/guardian is unable to provide parental permission in English or Spanish
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Premature babies: Study Intervention
Preterm infants born at gestational age less than 29 0/7 weeks requiring mechanical ventilation at 7-14 days of life (targeting N=12 participants completing study to 7 days post-intervention) |
Participants will receive 2 daily doses of Calfactant (3 ml/kg) intratracheal administration Participants will receive 2 daily doses of Budesonide (0.25mg/kg) intratracheal administration. |
|
Ingen indgriben: Premature babies: Standard of Care
Preterm infants born at gestational age less than 29 0/7 weeks requiring mechanical ventilation at 7-14 days of life (targeting N=12 participants completing study to 10 days post-randomization) |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Presence or absence of acute clinical deterioration up to 60 minutes after study intervention
Tidsramme: up to 60 minutes after study intervention (intervention received within 14 days of life (DOL))
|
Presence or absence of acute clinical deterioration - defined as desaturation less than 80 percent and/or bradycardia less than 100 beats per minute (bpm) - during the study intervention and up to 60 minutes after study intervention. |
up to 60 minutes after study intervention (intervention received within 14 days of life (DOL))
|
|
Presence or absence of severe acute clinical deterioration up to 60 minutes after study intervention
Tidsramme: up to 60 minutes after study intervention (intervention received within 14 DOL)
|
Presence or absence of severe acute clinical deterioration - defined as desaturation less than 60 percent and/or bradycardia less than 80 bpm - during the study intervention and up to 60 minutes after study intervention. |
up to 60 minutes after study intervention (intervention received within 14 DOL)
|
|
Occurrence of pneumothorax needing evacuation up to 48 hours after completion of study intervention
Tidsramme: baseline to 48 hours after completion of study intervention (intervention received within 14 DOL)
|
A yes or no question of whether there was pneumothorax (air in the pleural cavity) detected via chest x-ray, needing evacuation from baseline to 48 hours after completion of study intervention |
baseline to 48 hours after completion of study intervention (intervention received within 14 DOL)
|
|
Occurrence of pulmonary hemorrhages up to 48 hours after completion of study intervention
Tidsramme: baseline to 48 hours after completion of study intervention (intervention received within 14 DOL)
|
A yes or no question of whether pulmonary hemorrhage (bleeding in lungs) was observed in the endotracheal tube from baseline to 48 hours after completion of study intervention. |
baseline to 48 hours after completion of study intervention (intervention received within 14 DOL)
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Død eller Grad 3 Bronkopulmonal Dysplasi (BPD) inden 36 0/7 uger Postmenstruel Alder (PMA)
Tidsramme: op til 36 0/7 uger PMA
|
op til 36 0/7 uger PMA
|
|
|
Change in Respiratory Severity Score (RSS)
Tidsramme: Baseline to 7 days post-intervention (intervention received within 14 DOL)
|
RSS is the mean airway pressure multiplied by the fraction of inspired oxygen, a change toward higher scores indicates more severe respiratory symptoms. |
Baseline to 7 days post-intervention (intervention received within 14 DOL)
|
|
Days of mechanical ventilation by 36 0/7 weeks PMA
Tidsramme: up to 36 0/7 weeks PMA
|
Days of mechanical ventilation by 36 0/7 weeks PMA (If an infant died before 36 0/7 weeks, time from death to 36 0/7 weeks PMA will be considered as mechanical ventilation days) |
up to 36 0/7 weeks PMA
|
Samarbejdspartnere og efterforskere
Sponsor
Samarbejdspartnere
Efterforskere
- Ledende efterforsker: Dinushan Kaluarachchi, MBBS, University of Wisconsin, Madison
Datoer for undersøgelser
Studer store datoer
Studiestart (Anslået)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
- Urogenitale sygdomme
- Kvinders urogenitale sygdomme og graviditetskomplikationer
- Obstetrisk arbejde, for tidligt
- Obstetriske arbejdskomplikationer
- Graviditetskomplikationer
- Luftvejssygdomme
- Lungesygdomme
- Respirationsforstyrrelser
- For tidlig fødsel
- Respiratory Distress Syndrome
- Polycykliske forbindelser
- Graviditet
- Steroider
- SMUSED-RING-forbindelser
- Graviderede
- Gravidser
- Budesonid
- kalfaktant
Andre undersøgelses-id-numre
- 2024-1479
- A536757 (Anden identifikator: UW Madison)
- SMPH\PEDIATRICS\NEONATO (Anden identifikator: UW Madison)
- Protocol Version 10/09/25 (Anden identifikator: UW Madison)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-deling Understøttende informationstype
- STUDY_PROTOCOL
- ICF
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .